Fate Therapeutics, Inc.
HealthcareNASDAQ:FATE · NASDAQ Global Market
+$0.09 today
Vol 4.70M · Avg 2.82M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-65.8%
avg -51.3%
ROIC
-51.4%
avg -40.2%
ROA
-42.7%
avg -35.6%
Analysis
ROA is currently the strongest return metric at -42.7% versus its period average of -35.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Bahram Valamehr | President, Chief Executive Officer & Director | $964,700.00 | — | 49 | $635,762.00 | 0.55% |
Cindy R. Tahl | Chief Legal & Compliance Officer and Corporate Secretary | $732,700.00 | — | 53 | $628,155.00 | 0.54% |
Kamal Adawi | CFO & Treasurer | $541,973.00 | — | 47 | $100,000.00 | 0.09% |
Ryan Douglas | Senior Director of Investor Relations & Business Development | — | — | — | — | — |
Jessica Francis | Senior Vice President of Human Resources & Operations | — | — | — | — | — |
Martin Hosking | Head of Research | — | — | — | — | — |
Kate Duvall | Corporate Controller | — | — | — | — | — |
Tunde Babalola | Senior Vice President of Technical Operations & Quality | — | — | — | — | — |
Yu Cai | Head of Intellectual Property & Assistant General Counsel | — | — | — | — | — |
Andrew Henry | Senior Vice President of Clinical Operations | — | — | 62 | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
6
$144,367.45
Net Sentiment
$144,367.45
Net selling
Most Active
TAHL CINDY
3 transactions
Analysis
Insiders reported 0 buys worth $0.00 and 6 sells worth $144,367.45 over the last 12 months. That adds up to net selling of $144,367.45. TAHL CINDY was the most active insider with 3 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | -3.1% | +32.0% (15yr)3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Recent growth has been strongest in Revenue at -3.1% over three years. Forward estimates point to Revenue at +32.0% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Prelude Therapeutics Incorporated
NASDAQ:PRLD
$352.45M
Nkarta, Inc.
NASDAQ:NKTX
$204.62M
Alector, Inc.
NASDAQ:ALEC
$169.87M
Molecular Partners AG
NASDAQ:MOLN
$154.17M
Acumen Pharmaceuticals, Inc.
NASDAQ:ABOS
$143.56M
Corbus Pharmaceuticals Holdings, Inc.
NASDAQ:CRBP
$102.67M
PepGen Inc.
NASDAQ:PEPG
$101.68M
Vor Biopharma Inc.
NASDAQ:VOR
$98.42M
Cassava Sciences, Inc.
SAVA
$63.77M
Inovio Pharmaceuticals, Inc.
NASDAQ:INO
$58.95M
Who manages FATE?
Fate Therapeutics, Inc. (FATE) lists 10 active executives. The top listed executive is Ryan Douglas, Senior Director of Investor Relations & Business Development.
Are FATE insiders buying or selling?
Recent insider activity shows net buying of $30.84M.
Explore More
Continue the stock analysis
Jump to another research area for this company.